Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 62 articles: HTML format Text format

Single Articles

April 2019
1. NARDI V
   Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. Reply.
   N Engl J Med. 2019;380.
   PubMed     Text format    
   
   
   
2. FOULKES WD, Witkowski L
   Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer.
   N Engl J Med. 2019;380.
   PubMed     Text format    
   
   
   March 2019
3. MEHTA RS, Barlow WE, Albain KS, Vandenberg TA, et al
   Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
   N Engl J Med. 2019;380:1226-1234.
   PubMed     Text format     Abstract available
   
   
   
4. SCHMID P, Chui SY, Emens LA
   Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2019;380:987-988.
   PubMed     Text format    
   
   
   
5. ALTUNDAG K
   Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
   N Engl J Med. 2019;380:986-987.
   PubMed     Text format    
   
   
   
6. O'SULLIVAN H, Collins D, O'Reilly S
   Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
   N Engl J Med. 2019;380:986.
   PubMed     Text format    
   
   
   
7. AKTAS BY, Taban H, Aksoy S
   Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
   N Engl J Med. 2019;380:985-986.
   PubMed     Text format    
   
   
   February 2019
8. MCCAW ZR, Vassy JL, Wei LJ
   Palbociclib and Fulvestrant in Breast Cancer.
   N Engl J Med. 2019;380:796.
   PubMed     Text format    
   
   
   
9. TURNER NC, Huang X, Cristofanilli M
   Palbociclib and Fulvestrant in Breast Cancer. Reply.
   N Engl J Med. 2019;380:797.
   PubMed     Text format    
   
   
   
10. NAIK RD, Batra A, Gupta VG
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed     Text format    
    
    
    
11. BARDIA A, Mayer IA, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:741-751.
    PubMed     Text format     Abstract available
    
    
    
12. PROWELL TM, Beaver JA, Pazdur R
    Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.
    N Engl J Med. 2019;380:612-615.
    PubMed     Text format    
    
    
    
13. HAYES DF
    Further Progress for Patients with Breast Cancer.
    N Engl J Med. 2019;380:676-677.
    PubMed     Text format    
    
    
    
14. 
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    
    
    
    
15. JINDEEL A
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    
    
    
    January 2019
16. DEFILIPPIS EM, Nohria A, Burstein HJ, Doyle LA, et al
    A Breath-Taking Diagnosis.
    N Engl J Med. 2019;380:81-87.
    PubMed     Text format    
    
    
    December 2018
17. 
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2018;379:2582.
    PubMed     Text format    
    
    
    
18. VON MINCKWITZ G, Huang CS, Mano MS, Loibl S, et al
    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    N Engl J Med. 2018 Dec 5. doi: 10.1056/NEJMoa1814017.
    PubMed     Text format     Abstract available
    
    
    November 2018
19. ROCKSON SG
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2018;379:1937-1944.
    PubMed     Text format    
    
    
    
20. BARDIA A, Hovnanian MD, Brachtel EF, Nardi V, et al
    Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.
    N Engl J Med. 2018;379:1946-1953.
    PubMed     Text format    
    
    
    October 2018
21. CHLEBOWSKI RT, Pan K
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1684.
    PubMed     Text format    
    
    
    
22. PATEL A, Gupta VG
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-4.
    PubMed     Text format    
    
    
    
23. LOVE RR
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683.
    PubMed     Text format    
    
    
    
24. NEWMAN LA
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681-2.
    PubMed     Text format    
    
    
    
25. MCCAW ZR, Wei LJ, Kim DH
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681.
    PubMed     Text format    
    
    
    
26. CHENG Y, Wu Y, Wu L
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1.
    PubMed     Text format    
    
    
    
27. 
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-1685.
    PubMed     Text format    
    
    
    
28. 
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1682.
    PubMed     Text format    
    
    
    
29. SCHMID P, Adams S, Rugo HS, Schneeweiss A, et al
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1809615.
    PubMed     Text format     Abstract available
    
    
    
30. TURNER NC, Slamon DJ, Ro J, Bondarenko I, et al
    Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1810527.
    PubMed     Text format     Abstract available
    
    
    
31. 
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2018;379:1585.
    PubMed     Text format    
    
    
    
32. 
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385-1386.
    PubMed     Text format    
    
    
    
33. KANAKIS GA, Jorgensen N, Goulis DG
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385.
    PubMed     Text format    
    
    
    August 2018
34. LITTON JK, Rugo HS, Ettl J, Hurvitz SA, et al
    Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    N Engl J Med. 2018 Aug 15. doi: 10.1056/NEJMoa1802905.
    PubMed     Text format     Abstract available
    
    
    July 2018
35. STEARNS V
    TAILORing Adjuvant Systemic Therapy for Breast Cancer.
    N Engl J Med. 2018;379:191-192.
    PubMed     Text format    
    
    
    June 2018
36. GIORDANO SH
    Breast Cancer in Men.
    N Engl J Med. 2018;378:2311-2320.
    PubMed     Text format    
    
    
    
37. MULASI I
    The Scarlet Virus.
    N Engl J Med. 2018;378:2157-2159.
    PubMed     Text format    
    
    
    
38. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
    Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164.
    PubMed     Text format     Abstract available
    
    
    
39. LIPPMAN ME
    Endocrine Adjuvant Therapy for Localized Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMe1806130.
    PubMed     Text format    
    
    
    
40. SPARANO JA, Gray RJ, Makower DF, Pritchard KI, et al
    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1804710.
    PubMed     Text format     Abstract available
    
    
    May 2018
41. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed     Text format    
    
    
    March 2018
42. NACHTIGALL L, Naftolin F, Keefe DL
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1265.
    PubMed     Text format    
    
    
    
43. CRAMER DW, Braaten K
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264-8.
    PubMed     Text format    
    
    
    
44. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    
    
    
    
45. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    
    
    
    
46. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    PubMed     Text format    
    
    
    
47. 
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    PubMed     Text format    
    
    
    
48. 
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870-871.
    PubMed     Text format    
    
    
    
49. ANDERSON GM
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870.
    PubMed     Text format    
    
    
    January 2018
50. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:399-400.
    PubMed     Text format    
    
    
    
51. DONNEZ J, Dolmans MM
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:400-401.
    PubMed     Text format    
    
    
    December 2017
52. TURNER NC
    Signatures of DNA-Repair Deficiencies in Breast Cancer.
    N Engl J Med. 2017;377:2490-2492.
    PubMed     Text format    
    
    
    
53. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2017;377:2228-2239.
    PubMed     Text format     Abstract available
    
    
    
54. DEMICHELE A, Yee D, Esserman L
    Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2017;377:2287-2289.
    PubMed     Text format    
    
    
    
55. HUNTER DJ
    Oral Contraceptives and the Small Increased Risk of Breast Cancer.
    N Engl J Med. 2017;377:2276-2277.
    PubMed     Text format    
    
    
    November 2017
56. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    PubMed     Text format     Abstract available
    
    
    
57. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    PubMed     Text format    
    
    
    
58. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    PubMed     Text format    
    
    
    
59. 
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    PubMed     Text format    
    
    
    
60. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    PubMed     Text format    
    
    
    October 2017
61. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    PubMed     Text format    
    
    
    September 2017
62. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: